Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Study to Evaluate the Efficacy and Safety of MZL-IPI Risk-adapted Targeted Therapy in Patients With Untreated Marginal Zone B-cell Lymphoma

NCT06793189 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT06793189
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06793189 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Study to Evaluate the Efficacy and Safety of MZL-IPI Risk-adapted Targeted Therapy in Patients With Untreated Marginal Zone B-cell Lymphoma
Lead sponsor
Ruijin Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
January 23, 2025
Completion date
December 31, 2028
Enrollment
145 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

marginal zone lymphoma(mzl)